One of the greatest added values of the HU CFAR has been accelerated member access to new and emerging technologies. In the previous two competing submissions, these technologies have been largely provided through the Molecular Biology &Genomics Core and the Immunology Core. Services provided have focused largely on genomic and flow cytometic technologies, and have evolved over time, continuing to provide members with support that would be otherwise inaccessible to individual investigators. Based on our 2012 CFAR Strategic Review, the membership concluded that by integrating these cores and focusing on the intersection of advanced immunologic and genomic technologies and the increasing computational challenges associated with these, we could better leverage CFAR resources to serve members. These two cores were thus merged and redefined to form a single Advanced Technologies Core (ATC). The overall mission of the new Advanced Technologies Core is to provide access to advanced cytometric/genomic technologies and the computational methodologies that are an increasingly challenging barrier to individual investigators. At the current time, much of the identified need for members is in the capture of information regarding the phenotypic and functional state of individual cells, indexing these samples, and then capitalizing on this precious biomaterial to develop a comprehensive picture of the genomic landscape that exists in particular disease states. To ensure that all Harvard CFAR laboratories have access to this remarkable analytical power, this core will facilitate access to such technologies through the following aims: 1) Provide CFAR member access to state-of-the art technologies. 2) Providing user training in the above technologies, as well as computational assistance. 3) Building a virtual community using state of the art sharing and distribution tools.
A significant technology-driven revolution has occurred in the development of new flow cytometry, imaging and genomic technologies, that is critical to studies of virus-host interactions, therapeutic and prevention interventions, and vaccine development activities,-and the ATC aims to provide access to these advanced technologies and associated computational methodologies to the Harvard CFAR community.
|Jain, Sachin; Oldenburg, Catherine E; Mimiaga, Matthew J et al. (2016) High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. AIDS Behav 20:1556-63|
|Ballandras-Colas, Allison; Brown, Monica; Cook, Nicola J et al. (2016) Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. Nature 530:358-61|
|Krakower, Douglas S; Mayer, Kenneth H (2016) Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough? J Infect Dis 214:983-5|
|Sunshine, Sara; Kirchner, Rory; Amr, Sami S et al. (2016) HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-9|
|Saito, Akatsuki; Henning, Matthew S; Serrao, Erik et al. (2016) Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol 90:6918-35|
|Mayer, Kenneth H; Krakower, Douglas S; Boswell, Stephen L (2016) Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 315:867-8|
|Brown, Carolyn A; Suneja, Gita; Tapela, Neo et al. (2016) Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist 21:731-8|
|Krakower, Douglas S; Maloney, Kevin M; Grasso, Chris et al. (2016) Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. J Int AIDS Soc 19:21165|
|Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53|
|McDavitt, Bryce; Bogart, Laura M; Mutchler, Matt G et al. (2016) Dissemination as Dialogue: Building Trust and Sharing Research Findings Through Community Engagement. Prev Chronic Dis 13:E38|
Showing the most recent 10 out of 844 publications